{"id":102107,"date":"2025-12-05T04:10:07","date_gmt":"2025-12-05T04:10:07","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/sapu-nano-announce-deciparticle-led-biomarker-framework-identifying-tumors-most-likely-to-respond-to-iv-sapu003-an-intravenous-everolimus-nanomedicine\/"},"modified":"2025-12-05T04:10:07","modified_gmt":"2025-12-05T04:10:07","slug":"sapu-nano-announce-deciparticle-led-biomarker-framework-identifying-tumors-most-likely-to-respond-to-iv-sapu003-an-intravenous-everolimus-nanomedicine","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/sapu-nano-announce-deciparticle-led-biomarker-framework-identifying-tumors-most-likely-to-respond-to-iv-sapu003-an-intravenous-everolimus-nanomedicine\/","title":{"rendered":"Sapu Nano Announce Deciparticle\u2122 Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"justify\">San Diego, Calif., Dec.  05, 2025  (GLOBE NEWSWIRE) &#8212; S<em>apu Nano<\/em> today announced new biomarker data identifying a <strong>molecular signature that predicts sensitivity to Sapu003<\/strong>, the company\u2019s intravenous Deciparticle<sup>\u2122<\/sup> formulation of everolimus. These data will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) Dec 9-12. This work describes the first prospective biomarker framework for intravenous everolimus and establishes a foundation for mTOR therapy targeted to the patient populations most likely to benefit.<\/p>\n<p align=\"justify\">The analysis, which evaluated more than <strong>9,000 patient tumor samples<\/strong> across 20 cancer types, revealed that tumors exhibiting a <strong>High-RICTOR \/ Low-RPTOR gene-expression pattern<\/strong> show a significantly greater dependency on mTOR signaling and are therefore, more likely to respond to potent mTOR inhibition delivered by IV Sapu003.<\/p>\n<p align=\"justify\">The biomarker analysis demonstrated that:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\">Tumors with <strong>elevated RICTOR<\/strong> (mTORC2 activation) and <strong>suppressed RPTOR<\/strong> (limited mTORC1 scaffolding) show <strong>heightened reliance on mTORC2-AKT survival signaling<\/strong>.<\/li>\n<li style=\"text-align:justify;\">These tumors exhibit <strong>increased glycolytic flux, elevated metabolic stress markers, and reduced compensatory feedback<\/strong>, making them vulnerable to systemically distributed everolimus.<\/li>\n<li style=\"text-align:justify;\">This phenotype\/genotype was strongly enriched in:\n<ul type=\"circle\">\n<li style=\"text-align:justify;\">HR+\/HER2- breast cancer<\/li>\n<li style=\"text-align:justify;\">Lung adenocarcinoma<\/li>\n<li style=\"text-align:justify;\">Gastric cancer<\/li>\n<li style=\"text-align:justify;\">Renal cell carcinoma<\/li>\n<li style=\"text-align:justify;\">Ovarian cancer<\/li>\n<li style=\"text-align:justify;\">AML and T-cell malignancies<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p align=\"justify\">Across multiple datasets, patients with this signature had <strong>significantly worse survival<\/strong> with standard therapy, but showed <strong>predicted sensitivity to Sapu003<\/strong>.<\/p>\n<p align=\"justify\">This enables, for the first time, <strong>biomarker-enriched patient selection<\/strong> for an mTOR inhibitor.<\/p>\n<p align=\"justify\">\u201cUp to now mTOR inhibitor therapy has lacked an empirical patient selection strategy beyond tumor type,\u201d said <strong>Dr.<\/strong> <strong>Seymour Fein, Chief Medical Officer of Sapu Nano<\/strong>. \u201cThe High-RICTOR\/Low-RPTOR signature gives us, for the first time, a molecular map of which patients are most likely to benefit. The potential for targeting a more sensitive patient population combined with the consistent pharmacokinetic profile of Sapu003 administered intravenously creates an entirely new therapeutic opportunity for mTOR-driven cancers.\u201d<\/p>\n<p align=\"justify\"><strong>About Sapu003<\/strong><\/p>\n<p align=\"justify\">Sapu003 is a novel intravenous nanoparticle formulation of everolimus engineered using Sapu Nano\u2019s proprietary Deciparticle<sup>\u2122<\/sup> technology. It is designed to overcome the poor bioavailability, intestinal toxicity, and variable patient exposure seen with oral everolimus while enabling reliable, predictable weekly IV dosing.<\/p>\n<p align=\"justify\"><strong>About the Deciparticle<\/strong><sup><strong>\u2122<\/strong><\/sup><strong> Platform<\/strong><\/p>\n<p align=\"justify\">The Deciparticle<sup>\u2122<\/sup> platform is a proprietary nanotechnology engineered to encapsulate hydrophobic molecules as <strong>uniform, sub-20 nm nanoparticles<\/strong> for intravenous administration. The platform improves systemic exposure, reduces GI deposition, and supports precision delivery while maintaining manufacturability at clinical scale.<\/p>\n<p align=\"justify\"><strong>About Sapu Nano<\/strong><\/p>\n<p align=\"justify\">Sapu Nano is a clinical-stage biotechnology company developing Deciparticle<sup>\u2122<\/sup> nanomedicine therapeutics designed to optimize the delivery of hydrophobic oncology agents and peptide-based therapeutics. The company operates an integrated ISO-5 cGMP manufacturing facility supporting rapid progression from formulation to clinical trial supply.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uP5jz_Fq-5o33e2poCJRRl80MN4J10TT6vT8rWVu6d_EosLaVJ0LKWgHknviCf6UeZx3IkxqU-NZBKzjfT4eVSzCP6fyIDDvyooYikV_8Ws=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><strong>www.sapunano.com<\/strong><\/a>.<\/p>\n<p>Investor &amp; Media Contact<br \/>Sapu Nano (US) LLC<br \/>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j3342VNkEZXngO1K9D5dkG9uqKEHarFUxhBpIhoeWhFwGCYTzqFDKcrry_lC1zf8o0qJIg7aBYDjsuOhO_ZGhg==\" rel=\"nofollow\" target=\"_blank\" title=\"ir@sapubio.com\">ir@sapubio.com<\/a><\/p>\n<p>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>San Diego, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) &#8212; Sapu Nano today announced new biomarker data identifying a molecular signature that predicts sensitivity to Sapu003, the company\u2019s intravenous Deciparticle\u2122 formulation of everolimus. These data will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) Dec 9-12. This work describes the first prospective biomarker [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":102108,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/3cff3eca-b4d7-4fde-9b7f-dabb9bae4ac9","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-102107","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/102107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=102107"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/102107\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/102108"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=102107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=102107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=102107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}